Laboratories Combix which has a pure generics focus provides the right fit for Zydus’ entry strategy into a market that is estimated at $ 1.7 billion and is growing at 21.5% compared to 6% for the overall pharmaceutical market in 2007. The Spanish pharmaceutical market is the 5th largest in Europe.
Established in 2006, Combix with a sales and marketing focus has a solid portfolio covering 17 molecules. Additionally, it has a range of products that are pending launch or in the pipeline. The acquisition allows Zydus to jumpstart its business and leverage strengths in product development, a high quality, cost-competitive supply chain and operational efficiency.